Laserfiche WebLink
HF100 NINTH ENGROSSMENT REVISOR BD 1­10100-9 <br />113.1 (3) maintain safety criteria with which patients must comply as a condition of participation <br />113.2 in the registry program to prevent patients from undertaking any task under the influence <br />113.3 of medical cannabis flower or medical cannabinoid products that would constitute negligence <br />113.4 or professional malpractice; <br />113.5 (4) review and publicly report on existing medical and scientific literature regarding the <br />113.6 range of recommended dosages for each qualifying medical condition, the range of chemical <br />113.7 compositions of medical cannabis flower and medical cannabinoid products that will likely <br />113.8 be medically beneficial for each qualifying medical condition, and any risks of noncannabis <br />113.9 drug interactions. This information must be updated by December 1 of each year. The office <br />113.10 may consult with an independent laboratory under contract with the office or other experts <br />113.11 in reporting and updating this information; and <br />113.12 (5) annually consult with cannabis businesses about medical cannabis that the businesses <br />113.13 cultivate, manufacture, and offer for sale and post on the Division of Medical Cannabis <br />113.14 website a list of the medical cannabis flower and medical cannabinoid products offered for <br />113.15 sale by each medical cannabis retailer. <br />113.16 Subd. 3. Research. (a) The Division of Medical Cannabis must conduct or contract with <br />113.17 a third party to conduct research and studies using data from health records submitted to <br />113.18 the registry program under section 342.55, subdivision 2, and data submitted to the registry <br />113.19 program under section 342.52, subdivisions 2 and 3. If the division contracts with a third <br />113.20 party for research and studies, the third party must provide the division with access to all <br />113.21 research and study results. The division must submit reports on intermediate or final research <br />113.22 results to the legislature and major scientific journals. All data used by the division or a <br />113.23 third party under this subdivision must be used or reported in an aggregated nonidentifiable <br />113.24 form as part of a scientific peer -reviewed publication of research or in the creation of <br />113.25 summary data, as defined in section 13.02, subdivision 19. <br />113.26 (b) The Division of Medical Cannabis may submit medical research based on the data <br />113.27 collected under sections 342.55, subdivision 2, and data collected through the statewide <br />113.28 monitoring system to any federal agency with regulatory or enforcement authority over <br />113.29 medical cannabis flower and medical cannabinoid products to demonstrate the effectiveness <br />113.30 of medical cannabis flower or medical cannabinoid products for treating or alleviating the <br />113.31 svmbtoms of a aualifvina medical condition. <br />113.32 EFFECTIVE DATE. This section is effective January 1, 2024. <br />Article 1 Sec. 54. 113 <br />